Brokers Offer Predictions for Genmab A/S FY2025 Earnings

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for Genmab A/S in a research note issued to investors on Tuesday, January 21st. William Blair analyst M. Phipps now anticipates that the company will earn $1.38 per share for the year, down from their prior forecast of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

Several other equities analysts also recently commented on GMAB. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Down 3.8 %

NASDAQ GMAB opened at $20.97 on Thursday. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $31.88. The company has a market capitalization of $13.88 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97. The firm’s fifty day simple moving average is $21.07 and its 200-day simple moving average is $23.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same period last year, the company posted $0.47 earnings per share.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in the stock. Two Sigma Advisers LP lifted its stake in shares of Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after buying an additional 280,900 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. FMR LLC increased its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Genmab A/S by 6.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock worth $5,662,000 after buying an additional 14,165 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.